In July 2011, FDA began a pilot program to notify people of drug recalls before they are classified in an effort to expedite notifications of human drug product recalls to the public. FDA is now able to accomplish the goal of expedited notification within the Enforcement Report. These recalls are identified within the Enforcement Report by the label of “Not Yet Classified” in the “Classification” column. It is also possible to search the Enforcement Report for these “Not Yet Classified” recalls using the filter drop down menu. Therefore, as of September 15, 2017 FDA will discontinue the pilot program, and will no longer post drug recalls that are pending classification on this webpage. To see posted recalls that are pending classification go to the weekly Enforcement Report.
Torsemide is administered orally and intravenously. It is metabolized by the hepatic cytochrome P450 enzyme system and is a substrate for CYP2C9. In humans, three metabolites, one of which is active, are produced. The active metabolite does not contribute significantly to clinical activity. In normal adults, about 80% is cleared through hepatic metabolism and 20% is cleared in the urine as unchanged drug. In healthy adults, the elimination half-life is about hours.
Affected cytochrome P450 isoenzymes and drug transporters: CYP2C9
Torsemide is a substrate for CYP2C9. Theoretically, metabolism may be affected by drugs that are inhibitors of inducers of CYP2C9.